André Ferreira

André Ferreira

Auto-generated profile, based on publicly available information

André Ferreira

Division of Nephrology, Department of Medicine, Instituto Português de Oncologia do Porto, FG, E.P.E., Porto, Portugal

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2024 in Cureus
Verified
Journal Article
Open access
PDF file
AFAndré Ferreira
André Ferreira
JSJosé Brito da Silva
José Brito da Silva
MCMaria Teresa Chuva
Maria Teresa Chuva
JCJosé Maximino Costa
José Maximino Costa
DPDeolinda Pereira
Deolinda Pereira
JBJosé Brito-Da-Silva
José Brito-Da-Silva
Abemaciclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor used for hormone-receptor-positive and human epidermal growth factor receptor 2 (HER-2)-negative breast cancer, can lead to elevated serum creatinine without implications on the true renal function. Although clinical trials have shown no increase in other kidney function biomarkers, this may still represent a challenge in cancer patients. We report a case of a 74-year-old female who presented with creatinine and cystatin-C elevation during treatment with abemaciclib without an equivalent decrease in measured glomerular filtration rate (GFR) with renal scintigraphy. The confirmation of adequate kidney function allowed for the maintenance of treatments that would otherwise be limited by renal impairment. Healthcare providers should be aware of abemaciclib's effect on serum creatinine but should not eliminate the possibility of actual kidney injury. Alternative biomarkers for GFR assessment are recommended, although the usefulness of cystatin-C in patients receiving abemaciclib should be investigated in greater depth.

15 August 2019 in SPE Production & Operations
Verified
Journal Article
Closed access
HSHugo Santos
Hugo Santos
PPPaulo Paz
Paulo Paz
IKIgor Krettli
Igor Krettli
NRNey Reis
Ney Reis
HPHardy Pinto
Hardy Pinto
VBValter Estevão Beal
Valter Estevão Beal
Summary: Well interventions, especially in offshore wells, are costly and usually very time-consuming to conduct. This is related mainly to the need for a rig or a similar unit to perform these operations. In this paper we propose the development of an autonomous robot for rigless well interventions. The robot will be inserted through the tree using a special tool. This proposal will result in significant cost reduction by eliminating the rig when performing light–workover operations in offshore locations. This reduces intervention time because a simpler unit might be used to deploy the robot. Examples of operations that could be performed by the robot are production logging, gas–lift valve replacement, sliding–sleeve opening and closing, and plug insertion or removal. To evaluate this proposal, a conceptual robot was designed. The feasibility of this conceptual robot was evaluated theoretically. After that, a simplified test robot was constructed to test critical aspects experimentally, in laboratories, and in a test well. The traction system, energy storage, and a positioning algorithm were evaluated. In this paper we will outline the intervention strategy proposed, perform a theoretical evaluation of this proposal on the basis of the conceptual robot, and present experimental results obtained with the simplified test robot.

7 August 2025 in Nefrología (English Edition)
Verified
Journal Article
Open access
AFAndré Ferreira
André Ferreira
MRMarina Reis
Marina Reis
TCTeresa Chuva
Teresa Chuva
HFHugo Ferreira
Hugo Ferreira
ICInês Coelho
Inês Coelho
JCJosé Maximino Costa
José Maximino Costa
Acute kidney injury (AKI) is a frequent and severe complication in hospitalised cancer patients. However, overall data from in-hospital drug-related AKI in cancer patients is scarce. We aim to review the profile of moderate to severe drug-induced AKI in patients admitted to an oncology hospital over the last two decades and to assess renal and overall outcomes. 410 cases of drug-induced AKI KDIGO≥2 were analyzed, comparing between two decades from 2002 to 2021 in a comprehensive cancer center. The main differences were the introduction of new classes of cancer therapy (e.g., immune checkpoint inhibitors [ICPI] and tyrosine kinase inhibitors [TKI]), a decrease in nephrotoxicity due to platinum-based drugs, and an increase in nephrotoxicity caused by multiple drugs without cancer-directed therapy. Mortality was similar, but the need for haemodialysis (HD) was higher in the second decade (25.5% vs 36.6%, p=0.02). Multivariate analysis presented invasive mechanical ventilation and sepsis as risk factors for both HD and mortality, haematologic cancer as risk factors for HD, and the need for HD and multiple drugs without cancer-directed therapy as risk factors for mortality. Adequate drug surveillance and prophylaxis render cancer therapy as a relatively small contributor to drug-induced AKI in a comprehensive cancer center. Critically ill patients have a higher need for HD and mortality regardless of the nephrotoxic agent implied.

3 July 2023 in Portuguese Journal of Nephrology & Hypertension
Verified
Journal Article
Closed access
RPRaquel Pinto
Raquel Pinto
CNCentro Hospitalar Tondela-Viseu Serviço de Nefrologia
Centro Hospitalar Tondela-Viseu Serviço de Nefrologia
CFCarolina Ferreira
Carolina Ferreira
AFAndré Ferreira
André Ferreira
JMJoaquim Milheiro
Joaquim Milheiro
UNUnidade Local de Saúde de Matosinhos Serviço de Nefrologia
Unidade Local de Saúde de Matosinhos Serviço de Nefrologia

6 May 2025 in Journal Of Nephrology
Verified
Journal Article
Closed access
PDF file
AFAndré Ferreira
André Ferreira
HFHugo Ferreira
Hugo Ferreira
JCJosé Maximino Costa
José Maximino Costa

3 June 2025 in Nefrología
Verified
Journal Article
Open access
AFAndré Ferreira
André Ferreira
MRMarina Reis
Marina Reis
TCTeresa Chuva
Teresa Chuva
HFHugo Ferreira
Hugo Ferreira
ICInês Coelho
Inês Coelho
JCJosé Maximino Costa
José Maximino Costa